Ovapuldencel-T (AiVita Biomedical)

N/A

Report date: 2024/10/18 20:00:35

Base Information

Drug NameOvapuldencel-T (AiVita Biomedical)

Drug Alias NameOvarian cancer stem cell therapy - NeoStem OncologyAVOVA-1

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCaladrius Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAivita Biomedical Inc

Active IndicationsN/A

Inactive IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms

Other Information

ATC CodeN/A